SG11202002114RA - Claudin6 antibodies and methods of treating cancer - Google Patents

Claudin6 antibodies and methods of treating cancer

Info

Publication number
SG11202002114RA
SG11202002114RA SG11202002114RA SG11202002114RA SG11202002114RA SG 11202002114R A SG11202002114R A SG 11202002114RA SG 11202002114R A SG11202002114R A SG 11202002114RA SG 11202002114R A SG11202002114R A SG 11202002114RA SG 11202002114R A SG11202002114R A SG 11202002114RA
Authority
SG
Singapore
Prior art keywords
claudin6
antibodies
methods
treating cancer
cancer
Prior art date
Application number
SG11202002114RA
Inventor
Dylan Conklin
Dennis Slamon
Neil O'brien
Mike Palazzolo
Euw Erika Von
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of SG11202002114RA publication Critical patent/SG11202002114RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
SG11202002114RA 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer SG11202002114RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer

Publications (1)

Publication Number Publication Date
SG11202002114RA true SG11202002114RA (en) 2020-04-29

Family

ID=65723110

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002114RA SG11202002114RA (en) 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer

Country Status (15)

Country Link
US (2) US20200291111A1 (en)
EP (1) EP3826667B1 (en)
JP (1) JP2020536507A (en)
KR (1) KR20200070238A (en)
CN (1) CN111565744A (en)
AU (1) AU2018334434A1 (en)
BR (1) BR112020005196A2 (en)
CA (1) CA3076207A1 (en)
CZ (1) CZ2021138A3 (en)
GB (1) GB202103867D0 (en)
IL (1) IL273196A (en)
MX (1) MX2020002921A (en)
NO (1) NO20210351A1 (en)
SG (1) SG11202002114RA (en)
WO (1) WO2019056023A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001430SA (en) 2017-09-29 2020-04-29 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
EA202192146A1 (en) 2019-02-15 2021-11-09 Интиграл Молекьюлар, Инк. ANTIBODIES FOR CLAUDIN 6 AND THEIR APPLICATION
EP3941944A4 (en) * 2019-03-20 2022-11-30 The Regents of the University of California Claudin-6 bispecific antibodies
BR112021018608A2 (en) * 2019-03-20 2021-11-23 Univ California Antibodies to claudin-6 and drug conjugates
US11834512B2 (en) 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
CN112386687B (en) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 Stem cell exosome and application thereof in medicines and cosmetics
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
WO2023154814A2 (en) * 2022-02-09 2023-08-17 Sera Prognostics, Inc. Shbg and ibp4 antibodies and methods using same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (en) 1984-12-04 1993-08-15 Lilly Co Eli TUMOR TREATMENT IN MAMMALS.
CA2320193A1 (en) 1998-02-10 1999-08-19 Welfide Corporation Controlled release preparation
WO2000023096A2 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Combination therapy with vip antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
ATE395413T1 (en) 2001-12-03 2008-05-15 Amgen Fremont Inc ANTIBODIES CATEGORIZATION BASED ON BINDING PROPERTIES
US7917208B2 (en) 2002-10-04 2011-03-29 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
AU2007332473B2 (en) * 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
US8282990B2 (en) 2007-04-19 2012-10-09 Dong-A Pharmaceutical, Co., Ltd. Method for preparing a biodegradable polymer microsphere containing a glucose-regulating peptide
SG187457A1 (en) * 2008-01-11 2013-02-28 Univ Tokyo Anti-cldn6 antibody
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
BR112013029212B1 (en) * 2011-05-13 2020-05-19 Ganymed Pharmaceuticals Ag antibodies for the treatment of cancer expressing claudin-6
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
AU2014346792A1 (en) * 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
US10370423B2 (en) * 2014-04-01 2019-08-06 Biotech Cell & Gene thrapies GMBH Claudin-6-specific immunoreceptors and T cell epitopes

Also Published As

Publication number Publication date
US20220372134A1 (en) 2022-11-24
BR112020005196A2 (en) 2020-09-15
JP2020536507A (en) 2020-12-17
WO2019056023A3 (en) 2019-05-16
EP3826667B1 (en) 2024-04-17
CN111565744A (en) 2020-08-21
CA3076207A1 (en) 2019-03-21
KR20200070238A (en) 2020-06-17
MX2020002921A (en) 2020-09-28
EP3826667A2 (en) 2021-06-02
EP3826667A4 (en) 2022-07-27
NO20210351A1 (en) 2021-03-18
IL273196A (en) 2020-04-30
WO2019056023A2 (en) 2019-03-21
CZ2021138A3 (en) 2021-09-15
GB202103867D0 (en) 2021-05-05
US20200291111A1 (en) 2020-09-17
AU2018334434A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
IL267803A (en) Methods of treating cancer with anti-tim-3 antibodies
IL275663A (en) Methods of treating cancer
IL267804A (en) Methods of treating cancer with anti-pd-1 antibodies
IL269026A (en) Methods of treating tumor
HK1258098A1 (en) Methods of treating cancer
HK1253093A1 (en) Methods of diagnosing and treating cancer
HK1252272A1 (en) Methods of treating cancer using anti-ox40 antibodies
GB2557389B (en) Treatment of cancer with anti-lap monoclonal antibodies
IL273196A (en) Claudin6 antibodies and methods of treating cancer
IL289663A (en) Claudin18 antibodies and methods of treating cancer
IL266990A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
IL262342A (en) Methods of treating cancer
HK1251927A1 (en) Novel biomarkers and methods of treating cancer
SG11202010793UA (en) Methods of treating cancer
ZA201908539B (en) Method of treatment of cancer
IL272810A (en) Methods of diagnosing and treating lung cancer
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
SG11202005163PA (en) Methods of treating cancer
IL281600A (en) Methods of treating cancer
IL277981A (en) Methods of treating cancer
ZA202002144B (en) Antibodies and methods of use
IL269123A (en) Methods of treating cancer
EP3585819A4 (en) Antibody constructs and methods of treating cancer
SG11202108140SA (en) Anti-bag2 antibody and methods of treating cancer
GB201720089D0 (en) Means and methods for treating cancer